SCHEMBL8461

SCHEMBL8461

Clc1ccnc2ccncc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.45
AXL P30530 1/20 0.44
PRKCI P41743 1/20 0.44
EGFR P00533 3/20 0.41
CCNC P24863 4/20 0.39
CDK8 P49336 4/20 0.39
SLC22A12 Q96S37 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
NR4A2 P43354 1/20 0.37
DAO P14920 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8128 0.83 GAA (0.45) GAAAXLPRKCIEGFRDYRK1B
SCHEMBL2008208 0.74 CCNC (0.39) EGFRCCNCCDK8SLC22A12KDM4E
SCHEMBL18574397 0.74 CCNC (0.39) EGFRCCNCCDK8SLC22A12KDM4E
SCHEMBL3577754 0.74 AXL (0.47) AXLPRKCIEGFRCCNCCDK8
SCHEMBL16247883 0.74 DYRK1A (0.39) EGFRCCNCCDK8SLC22A12KDM4E
SCHEMBL3147611 0.74 CCR1 (0.46) EGFRCCNCCDK8SLC22A12KDM4E
SCHEMBL2879912 0.74 NCF1 (0.57) GAAAXLEGFRCCNCCDK8
SCHEMBL277030 0.74 SLC22A12 (0.42) EGFRCCNCCDK8SLC22A12KDM4E
SCHEMBL277031 0.74 EP300 (0.47) EGFRCCNCCDK8SLC22A12KDM4E
SCHEMBL3147605 0.74 CCNC (0.39) EGFRCCNCCDK8SLC22A12KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103145709-A Synthesis process for 4-chloro-1,6-naphthyridine SUZHOU KEJIE BIOLOG PHARMACEUTICAL CO LTD 2013-06-12 CN claimed
EP-1075478-B1 PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 2003-04-16 EP claimed
US-20240360131-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 US disclosed
US-12065437-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-20 US disclosed
EP-3691642-B1 [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-03-06 EP disclosed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 CN disclosed
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
EP-4214199-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 EP disclosed
EP-1724268-A1 COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-22 EP disclosed
WO-2006069805-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2006-07-06 WO disclosed
EP-1075478-B1 PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 2003-04-16 EP disclosed
US-6372757-B1 OREXIN RECEPTORS FOR SLEEP DISORDERS AND EATING DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-04-16 US disclosed
US-4716170-A 5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-1,6-naphthyridin-2(1H)-ones and their cardiotonic use STERLING DRUG INC. (US) 1987-12-29 US disclosed
US-4697021-A 1,6-dihydro-6-oxo-3-pyridinecarbonitriles, intermediates for cardiotonic agents STERLING DRUG INC. (US) 1987-09-29 US disclosed
US-4657915-A INOTROPIC AGENTS STERLING DRUG INC. (US) 1987-04-14 US disclosed
US-4634772-A 2-[2-(di-lower-alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitriles, intermediates for cardiotonic agents STERLING DRUG INC. (US) 1987-01-06 US disclosed
EP-0189853-A2 1,6-Naphthyridin-2(1H)-ones having cardiotonic activity and preparation STERLING DRUG INC. (US) 1986-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR GAA 829/4885AXL 2809/4885PRKCI 216/4885
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK2A1 GAA 1307/4885AXL 2738/4885PRKCI 42/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C GAA 1936/4885AXL 1942/4885PRKCI 749/4885
US-12065437-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS GAA 2589/4885AXL 1890/4885PRKCI 276/4885
US-20240360131-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS GAA 2589/4885AXL 1890/4885PRKCI 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.